After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga ...

A new survey from SiriusXM Media details the issues that many people have with the current state of TV drug ads—and ...

While argenx has been able to demonstrate the merit of its FcRn drug Vyvgart in multiple autoimmune indications, not every ...

After a three-decade drought of new antibiotics to treat gonorrhea, the FDA has signed off on two first-in-class oral ...

Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...

After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...

About a year and a half after telegraphing plans to shift its headquarters from New Jersey to Philadelphia, CDMO Adare Pharma ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...